Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Tempus AI, Inc. - Class A Common Stock (NQ: TEM )

34.81 -0.73 (-2.04%)
Streaming Delayed Price Updated: 3:06 PM EST, Dec 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Tempus AI, Inc. - Class A Common Stock

< Previous 1 2 3 Next >
Oncology Advancements Accelerate Amid Rising Early-Onset Cancer Diagnoses
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:CRDF),(NASDAQ:PSNL),(NASDAQ:TEM),(NASDAQ:CKPT) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence COVID-19
Tempus AI: A Potential Double-Bagger After Recent Pullback
AI healthcare stock Tempus AI has seen its value fall off a cliff recently. However, Wall Street remains bullish, seeing significant upside in the shares. 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Tempus Now an In-Network Provider for Blue Cross Blue Shield Illinois, Blue Shield California, and Avalon Healthcare Solutions
From Tempus
Via Business Wire
Why Healthcare Providers Are Increasingly Trusting Artificial Intelligence for Detection & Diagnosis
EQNX::TICKER_START (OTCQB:AVAI),(NASDAQ:TEM),(NYSE:MDT),(NYSE:SYK),(NASDAQ:PEGA) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence Climate Change
Exposures Artificial Intelligence Climate
New CMS Decision Provides Medicare Coverage for the Clinical Use of the Tempus ECG-AF Device
From Tempus AI, Inc.
Via Business Wire
Why Healthcare Providers Are Increasingly Trusting Artificial Intelligence for Detection & Diagnosis
From FN Media Group LLC
Via GlobeNewswire
Personalis and Tempus Expand Collaboration to Biopharma
From Personalis, Inc.
Via Business Wire
Cathie Wood's Ark Invest Trims Tesla Exposure Amid Searing Rally, Sells $21.8M Worth Of Stock — Bets On This AI Medical Company
On Wednesday Dec. 11, 2024, Cathie Wood-led Ark Invest sold $21.8 million worth of Tesla shares. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Artificial Intelligence (AI) Redefining Medical Diagnostics Industry That’s Expected to be a $7.2 Billion Market by 2029
EQNX::TICKER_START (OTCQB:AVAI),(OTCQX:RHHBY),(NASDAQ:RXRX),(NASDAQ:TEM),(NASDAQ:ISRG) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence
Tempus to Participate in the Piper Sandler 36th Annual Healthcare Conference
From Tempus AI, Inc.
Via Business Wire
Artificial Intelligence (AI) Reshaping Healthcare Industry with Unimaginable Potential
EQNX::TICKER_START (OTCQB:AVAI),(NYSE:TDOC),(NASDAQ:TEM),(NYSE:MDT),(NASDAQ:CLOV) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence Fraud
Exposures Artificial Intelligence Legal
Ray Dalio's Bridgewater Cuts Stake In Microsoft Stock By 20% – Is Big Tech Losing Its Shine?
Ray Dalio's Bridgewaterand Ark Invest trimmed their Microsoft positions, signaling a shift in Big Tech's role in portfolios. 
Via Benzinga
How AI is Shaping the Future of Healthcare: Key Advances in Diagnostics and Precision Medicine
EQNX::TICKER_START (OTCQB:AVAI),(NYSE:BFLY),(NASDAQ:TEM),(NASDAQ:GEHC),(NASDAQ:RDNT) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence
Artificial Intelligence (AI) Reshaping Healthcare Industry with Unimaginable Potential
From FN Media Group LLC
Via GlobeNewswire
Tempus Molecular Profiling Integration Now Available Through Flatiron’s OncoEMR®
From Tempus AI, Inc.
Via Business Wire
Donald Trump Victory Week (Nov 4-8): These Large Cap Stocks Were Biggest Gainers
Top-performing large-cap stocks last week: APP (+82.27%), TEM (+49.03%), COIN (+45.35%), ALAB (+42.57%), PLTR (+41.0%), AXON (+39.76%), DOCS (+39.29%), TSLA (+32.28%), HOOD (+25.58%), RDDT (+23.64%). 
Via Benzinga
Topics Government
Exposures Political
Tempus Publishes Study Highlighting Benefits of Concurrent RNA and DNA Sequencing in Advanced Cancer Care
From Tempus AI, Inc.
Via Business Wire
Sapiens International Posts Downbeat Results, Joins Sky Harbour And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Nvidia To Rally More Than 18%? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
Why Revelation Biosciences Shares Are Trading Higher By Around 49%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Sony Posts Upbeat Earnings, Joins Tesla, Upstart, Doximity, Fortrea, Axon Enterprise And Other Big Stocks Moving Higher On Friday
Via Benzinga
Tempus Announces Nine Abstracts Accepted for Presentation at the 2024 Society for Immunotherapy of Cancer Annual Meeting
From Tempus AI, Inc.
Via Business Wire
Tempus Announces the Clinical Launch of its Immune Profile Score Algorithmic Test
From Tempus AI, Inc.
Via Business Wire
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Tempus Reports Third Quarter 2024 Results and Agreement to Acquire Ambry Genetics
From Tempus AI, Inc.
Via Business Wire
Tempus to Report Third Quarter 2024 Financial Results on November 4
From Tempus AI, Inc.
Via Business Wire
Tempus to Report Third Quarter 2024 Financial Results on November 7
From Tempus AI, Inc.
Via Business Wire
Tempus Announces Expansion of Collaboration with Takeda to Leverage Multimodal Real-World Datasets and Biological Model Systems in Oncology Research and Development
From Tempus AI, Inc.
Via Business Wire
Tempus AI Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating
A Relative Strength Rating upgrade for Tempus AI shows improving technical performance. 
Via Investor's Business Daily
Topics Artificial Intelligence
Exposures Artificial Intelligence
Tempus Launches Beta Version of olivia, its AI-enabled Personal Health Concierge App for Patients
From Tempus AI, Inc.
Via Business Wire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.